NCT06902467View on ClinicalTrials.gov

Combined Intraperitoneal Chemotherapy Regimen After Optimal Interval Surgery in Advanced Ovarian Cancer: BICOV-1 (Bidirectional Chemotherapy in Ovarian Cancer)

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

March 15, 2026

Study Completion Date

December 15, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstron

Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstrong 8 and modified by GEICO 18: IV paclitaxel 175 mg /m2 (day 1) + IP cisplatin 100 mg/m2 (day 2) + IP paclitaxel 60 mg/m2 (day 8).

Trial Locations (1)

30120

RECRUITING

HCUVA, Murcia

All Listed Sponsors
lead

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

OTHER